Osteonecrosis of the jaw as an adverse effect of therapy in urological cancer patients
Authors:
Lukáš Hauer 1; Daniel Hrušák 1; Jan Jambura ml. 1; Milan Hora 2
Authors‘ workplace:
Stomatologická klinika LF UK a FN, Plzeň
1; Urologická klinika LF UK a FN, Plzeň
2
Published in:
Ces Urol 2013; 17(2): 88-99
Category:
Review article
Overview
Drug-related osteonecrosis of the jaw is a rare complication from treatment in patients suffering from cancer and other diseases. These lesions are described as an adverse effect of a specific type of antiresorptive and/or biological therapy, which affects bone metabolism. The risk of osteonecrosis of the jaw is significantly higher in cancer patients than in patients with metabolic bone diseases. Patients suffering from advanced urological malignancies represent a group with a high risk for the development of these lesions. Osteonecrosis of the jaw impairs the quality of life for those affected. It may significantly restrict or completely prevent food intake. The drug-related osteonecrosis of the jaw is a condition that has only recently been described. As a result, the pathophysiology of these lesions is still poorly understood, and a consensus on the treatment has not been reached. Since the therapy of the jaw osteonecrosis is challenging, long lasting, and often has limited success, emphasis needs to be placed on preventive measures. The authors present a literature review and summarize the current knowledge about these lesions.
Key words:
bisphosphonates, denosumab, bevacizumab, sunitinib, adverse effects, osteonecrosis of the jaw, cancer patient.
Sources
1. Hauer L, Hrušák D, Hostička L, et al. Osteonekróza čelistí v souvislosti s celkovou léčbou bisfosfonáty – doporučení pro praxi. LKS 2011; 21(5): 94–105.
2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61(9): 1115–1117.
3. Estilo CL, Fornier M, Farooki A, et al. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 2008; 26(24): 4037–4038.
4. Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg 2010; 48(3): 221–223.
5. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28(35): 5132–5139.
6. Koch FP, Walter C, Hansen T, Jager E, Wagner W. Osteonecrosis of the jaw related to sunitinib. Oral Maxillofac Surg 2011; 15(1): 63–66.
7. Ruggiero SL, Dodson TB, Assael LA, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws – 2009 update. J Oral Maxillofac Surg 2009; 67(5 Suppl): 2–12.
8. Yamashita J, McCauley LK. Antiresorptives and osteonecrosis of the jaw. J Evid Based Dent Pract. 2012; 12(3 Suppl): 233–247.
9. Tennis P, Rothman KJ, Bohn RL, et al. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf 2012; 21(8): 810–817.
10. Christodoulou C, Pervena A, Klouvas G, et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009; 76(3): 209–211.
11. Aragon-Ching JB, Ning YM, Chen CC, et al. Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti–angiogenic agents. Cancer Invest 2009; 27(2): 221–226.
12. Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol 2010; 136(8): 1117–1124.
13. Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23(6): 826–836.
14. Jadu F, Lee L, Pharoah M, Reece D, Wang L. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 2007; 18(12): 2015–2019.
15. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353(1): 99–102.
16. Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in pa-tients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006; 91(7): 968–971.
17. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23(34): 8580–8587.
18. Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006; 134(6): 620–623.
19. Fehm T, Beck V, Banys M, et al. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 2009; 112(3): 605–609.
20. Sanna G, Preda L, Bruschini R, et al. Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Ann Oncol 2006; 17(10): 1512–1516.
21. Lo JC, O’Ryan FS, Gordon NP, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010; 68(2): 243–253.
22. Otto S, Abu-Id MH, Fedele S, et al. Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence – a multi-centre study. J Craniomaxillofac Surg 2011; 39(4): 272–277.
23. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377(9768): 813–822.
24. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011; 29(9): 1125–1132.
25. Fleissig Y, Regev E, Lehman H. Sunitinib related osteonecrosis of jaw: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 113(3): e1–3.
26. Troeltzsch M, Woodlock T, Kriegelstein S, et al. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw. J Can Dent Assoc 2012; 78: c85.
27. Dişel U, Beşen AA, Özyılkan Ö, Er E, Canpolat T. A case report of bevacizumab-related osteo-necrosis of the jaw: old problem, new culprit. Oral Oncol 2012; 48(2): e2–3.
28. Guarneri V, Miles D, Robert N, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 2010; 122(1): 181–188.
29. Epstein MS, Ephros HD, Epstein JB. Review of current literature and implications of RANKL inhibitors for oral health care providers. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; http://dx.doi.org/10.1016/j.oooo.2012.01.046.
30. Otto S, Schreyer C, Hafner S, et al. Bisphosphonate-related osteonecrosis of the jaws – characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg 2012; 40(4): 303–309.
31. Gordon CR, Rojavin Y, Patel M, et al. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg 2009; 62(6): 707–709.
32. Sawatari Y, Marx RE. Bisphosphonates and bisphosphonate induced osteonecrosis. Oral Maxillofac Surg Clin North Am 2007; 19(4): 487–498.
33. Hauer L., Baxa J., Hrušák D., Hostička L., Andrle P. Využití zobrazovacích vyšetřovacích metod při diagnostice osteonekrózy čelistí vzniklé v souvislosti s léčbou bisfosfonáty. Prakt zub Lék 2012; 60(1): 4–13.
34. Lazarovici TS, Yahalom R, Taicher S, et al. Bisphosphonate related osteonecrosis of the jaws: a single-center study of 101 patients. J Oral Maxillofac Surg 2009; 67(4): 850–855.
35. Holzinger D, Seemann R, Klug C, et al. Long-term success of surgery in bisphosphonate-related osteonecrosis of the jaws (BRONJs). Oral Oncol 2013; 49(1): 66–70.
36. Stockmann P, Vairaktaris E, Wehrhan F, et al. Osteotomy and primary wound closure in bisphosphonate–associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer 2010; 18(4): 449–460.
37. Carlson ER, Basile JD. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009; 67(5 Suppl): 85–95.
38. Williamson RA. Surgical management of bisphosphonate induced osteonecrosis of the jaws. Int J Oral Maxillofac Surg 2010; 39(3): 251–255.
39. Ripamonti CI, Maniezzo M, Campa T, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009; 20(1): 137–145.
40. Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011; 29(9): 1221–1227.
Labels
Paediatric urologist Nephrology UrologyArticle was published in
Czech Urology
2013 Issue 2
Most read in this issue
- Osteonecrosis of the jaw as an adverse effect of therapy in urological cancer patients
- A case report of hydronephrosis affecting a large segment of a horseshoe kidney
- Lower urinary tract obstruction caused by benign prostatic hyperplasia in patients with end stage renal disease
- Comparison of long term outcomes after ileal and gastric bladder augmentation